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INTRODUCTION 
Mushrooms are macroscopic members of the third largest kingdom on 
Earth, Fungi. They do not represent a well-defined taxonomic category: 
according to the definition of Chang and Miles a mushroom is “a 
macrofungus with a distinctive fruiting body, which can be hypogeous or 
epigeous, large enough to be seen with the naked eye and to be picked by 
hand”. For a long time, mushrooms have been playing an important role in 
several aspects of human life. Edible mushrooms are used as part of a 
regular diet, while some mushrooms with psychedelic properties have been 
applied in religious ceremonies. The so called medicinal mushrooms are 
popular healing agents which are widely used in traditional medicines of 
several countries in the Far East for thousands of years. 
On the basis of our current scientific knowledge the estimated 
number of mushroom species is about 140 000, however only 10% of these 
are known to science. Approximately 700 species of higher Basidiomycetes 
have been found to possess diverse pharmacological properties. The 
spectrum of identified pharmacological activities of Basidiomycetes is very 
broad. Among these bioactivities the antitumor and antimicrobial effects 
are the most extensively studied. 
In the last decades bacterial resistance to first-choice antibiotics 
have become a problem with global impact on human population. The 
appearance of mushroom compounds in antibacterial therapy dates back to 
1979, when tiamulin, a semisynthetic derivative of pleuromutilin was 
approved for veterinary purposes. In 2007, retapamulin, another 
pleuromutilin derivative was approved by the US FDA for the topical 
treatment of impetigo. 
Cancer is a leading cause of death in both more and less 
economically developed countries. More recently, some species of higher 
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Basidiomycetes have been found to markedly inhibit the growth of different 
tumor cell lines. The anticancer and immunomodulatory beta-glucans, 
lentinan from Lentinus edodes and krestin from Trametes versicolor, are 
probably the best known medical agents of mushroom origin. Besides, 
low-molecular-weight fungal metabolites with a wide variety of chemical 
structures have been also identified as antitumor agents in the last decades, 
such as illudins (sesquiterpenes), ganoderic acids (triterpenes) and 
terreumols (meroterpenoids), among others. 
AIMS OF THE STUDY 
In 2012 the research group of the Department of Pharmacognosy at 
University of Szeged started a screening program to investigate the 
antiproliferative and antimicrobial activities of the mushroom species 
native to Hungary with the purpose of obtaining potential antineoplastic 
and antimicrobial compounds. The aim of the presented study - as a part of 
this project - the chemical investigation and identification the bioactive 
compounds of the selected four mushroom species belonging to the 
Basidiomycetes (Gymnopus fusipes (Bull.:Fr.) Gray, Tricholoma 
populinum J.E.Lange, Scleroderma bovista Fr., Tapinella atrotomentosa 
(Batsch) Šutara). 
In order to achieve the aims, the main tasks were: 
 Review of the literature on the selected species, from the aspect of 
the chemistry and pharmacological properties. 
 Investigation of the tumor cell proliferation-inhibitory effect and 
the susceptibility of Gram-positive and –negative bacteria against 
the fungal extracts. 
 Extraction of the mushroom material of the selected species for 
preparative work. 
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 Isolate the compounds responsible for the antiproliferative or 
antimicrobial effects via bioactivity-directed fractionation, using 
various chromatographic techniques. 
 Elucidate the structures of the isolated compounds by NMR and 
MS methods. 
 Evaluate the pharmacological potential of the isolated compounds. 
MATERISLS AND METHODS 
For antiproliferative and antimicrobial screening, mushroom species were 
collected in north-eastern part of Hungary in 2013–2014. For preparative 
mycochemical work fruiting bodies of G. fusipes (2 kg) were collected in 
northern part of Hungary in July of 2013. Mushroom materials of 
T. populinum (3 kg), S. bovista (4 kg) and T. atrotomentosa (2 kg) were 
collected in the vicinity of Szeged in successive years of 2013, 2014 and 
2015. 
In the initial step of the preparative work, the freeze-dried or raw 
mushroom materials were percolated with an amphipolar solvent (MeOH). 
The concentrated extracts were diluted with 50% methanol and liquid–
liquid extraction was employed, which resulted in n-hexane and chloroform 
phases. For the screening, H2O-soluble extracts were also prepared. 
The investigated extracts were fractionated with different type of 
multistep chromatographic procedures including open-column 
chromatography (OCC), rotation planar chromatography (RPC), flash 
column chromatography (FCC) and high-performance liquid 
chromatography (HPLC). Normal- or reversed-phase SiO2 were applied as 
stationary phases. 
The structures of the obtained compounds were characterized by 
spectroscopic methods (NMR and MS). However, the structure elucidation 
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of compounds 1-2 required the combination of spectral methods, Marfey’s 
analysis and molecular modeling. 
The antiproliferative properties of the extracts and isolated 
compounds were determined by means of MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assay on a panel of human adherent 
cancer cell lines including cervix carcinoma (HeLa), ovarian carcinoma 
(A2780), skin epidermoid carcinoma (A431) and three different human 
breast carcinoma (MCF-7, MDA-MB-231 and T47D) cell lines. 
Antimicrobial effects were measured against 11 standard and 
9 clinical isolates by standard disc-diffusion method. In the case of 
diameter of inhibition zone ≥10 mm the extracts and the compounds were 
further subjected to determine their minimal inhibitory concentration 
(MICs) by microdilution method. For the detection of positive interaction 
between antibiotic drugs and extracts or pure compounds double-disc 
synergy assay was applied. 
The xanthine-oxidase inhibitory activity was evaluated using a 
spectrophotometric method based on the measurement of uric acid 
production from xanthine at 290 nm with plate reader. 
The in vitro antioxidant activity was investigated by DPPH and 
ORAC assays. The studies were carried out on a 96-well microplate using 
FlUOStar Optima plate reader. 
RESULTS AND DISCUSSION 
Screening of Basidiomycetes species for antiproliferative and 
antimicrobial activities 
The aim of our studies was to perform an extensive screening program for 
the evaluation of mushrooms native to Hungary in terms of their potential 
antiproliferative and antimicrobial activities. 
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The organic and water extracts of selected mushroom species were 
tested in vitro for their antiproliferative activity against several human 
cancer cell lines. The chloroform extract of G. fusipes exerted outstanding 
effect on the investigated human cancer cells. The chloroform extract of 
S. bovista proved to possess notable antiproliferaive activity, while the 
extracts of T. populinum were found to exhibit moderate antiproliferative 
effects. 
In our antimicrobial screening assay 40 species were tested in vitro 
against 11 standard bacterial strains and 9 clinical isolates including 
resistant and multi-drug resistant bacteria. 16 species exhibited antibacterial 
effects with moderate to high potential. The chloroform extract of 
T. atrotomentosa demonstrated the broadest antibacterial spectrum, it was 
found to be effective against Gram-positive bacterial strains, and also 
against standard and ESBL-positive E. coli, standard and multiresistant 
P. aeruginosa and multiresistant A. baumannii. 
The active mushroom extracts were applied to different 
multiresistant micro-organisms combined with commercial antibiotics to 
evaluate their capacity to potentiate the action of standard drugs. The 
extracts T. atrotomentosa exhibited synergistic activity with cefuroxime 
against methicillin resistant Staph. aureus.  
Isolation of the compounds of G. fusipes 
The chloroform fraction of G. fusipes was separated 
first by RPC, then the subfraction B III was further 
purified with RP-HPLC using acetonitrile – water 
gradient eluent system (Figure 1). This purification 
process led to the isolation of 2 novel natural 
compounds COFUB1 (1) and COFUB2 (2). 
Figure 1. Isolation of compounds from G. fusipes 
6 
 
Isolation of the compounds of T. populinum 
In the case of T. populinum the n-hexane phase was fractionated by OCC 
and the combined fractions were further analyzed using repeated FCC 
(Figure 2). Thanks to chromatographic separation six compounds were 
isolated: TRIPOA5 (3), TRIPOA4 (4), TRIPOA1 (5), TRIPOA3 (6), 
TRIPOA6 (7) and TRIPOA2 (8). The purification of the chloroform extract 
of the species was separated with RPC followed by RP-HPLC affording 
four compounds, two in pure form [TRIPOB1 (9), TRIPOB3 (10)] and two 
in a mixture of epimeric forms [TRIPOB2 (11), TRIPOB4 (12)]. 
 
Figure 2. Isolation of compounds from Tricholoma populinum 
Isolation of the compounds of S. bovista 
The separation of n-hexane extract of S. bovista was carried out using open-
column chromatography (OCC) (Figure 3). The combined fractions were 
further separated by flash column chromatography (FCC), which resulted in 
five compounds: SCLEBOA4 (3), SCLEBOA5 (4), SCLEBOA3 (5), 
SCLEBOA2 (8) and SCLEBOA1 (13). The analysis of the chloroform 
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fraction of this species was performed by repeated FCC to obtain two 
compounds SCLEBOB1 (14) and SCLEBOB2 (15). 
 
Figure 3. Isolation of compounds from Scleroderma bovista 
Isolation of the compounds of T. atrotomentosa 
The chloroform phase of T. atrotomentosa was separated by repeated FCC 
steps (Figure 4).  
 
Figure 4. Isolation of compounds from Tapinella atrotomentosa 
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The obtained fractions were purified in each case by NP-HPLC 
using n-hexane – isopropanol – water isocratic eluent system. Utilization of 
combined chromatographic separation techniques led to the isolation of 
four compounds: PAXATRB1 (16), PAXATRB2 (17), PAXATRB5 (18) 
and PAXATRB6 (19). 
Cyclopeptides from Gymnopus fusipes 
From the chloroform extract of G. fusipes two novel cyclic 
octadecapeptides were isolated, namely gymnopeptides A (1) and B (2) 
(Figure 5). To best of our knowledge, they are the largest cyclopeptides 
among the mushroom metabolites. Gymnopeptides A (1) and B (2) are 
constituted of 18 amino acids (three alanine, four valine, two N-methyl-
glycine (Sar), an N-methyl-alanine, seven N-methyl-valine and a serine/ 
threonine residues). The isolated compounds differ only in one amino acid; 
serine was found in 1 replaced by a threonine in 2.  
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Figure 5. AA sequences of gymnopeptides A (1) (R = H)  
and B (2) (R = CH3) 
Gymnoppetides A and B are highly methylated, the number of 
N-methylated amino acids is 10 out of 18 in each cyclopeptide. The 
unmodified and N-methylated amino acids alternate in the sequences of the 
two cyclopeptides, except in position 11. Among the secondary metabolites 
of higher mushrooms cyclic peptides are fairly rare compounds. Apart from 
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(−)-ternatin, a highly N-methylated cyclic heptapeptide isolated from the 
medicinal mushroom Trametes versicolor, cyclopeptides have been 
identified in few genera of poisonous species (Amanita, Conocybe, 
Galerina, Lepiota and Omphalotus). 
Steroids and sulfinyladenosine compounds from Tricholoma populinum 
In the methanol extract of T. populinum ten compounds (3-12) have been 
identified, 9 of them for the first time in this species. The structure 
determination of compounds revealed that 3-8 are triterpene steroids 
possess ergostane structure: ergosterol (3), 3β-hydroxyergosta-7,22-diene 
(4), cerevisterol (5), 3β,5α,6β,9α-tetrahydroxyergosta-7,22-diene (6), 
methylated derivative of cerevisterol (7) and glucopyranosyl-5,8-
epidioxyergosta-6,22-diene (8). 
Nicotinamide (9) has been previously detected by Turner et al. 
(1987) in T. populinum samples from British Columbia. Besides, 
compounds 10-12 proved to be adenosine type compounds. The 
methylsulfinyladenosine structures of 11 and 12 (epimers of 5’-deoxy-5’-
methylsulphinyladenosine) represent a fairly rare subclass of secondary 
metabolites. 
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Ceramide and steroid type compounds from Scleroderma bovista 
The mycochemical examination of S. bovista led to the isolation of seven 
compounds (3-5, 8, 13-15). In the n-hexane phase of S. bovista a ceramide 
type compound linked to a glucose molecule, namely cerebroside B (13) 
was detected. The investigation of the species resulted in the identification 
of 6 triterpene steroids: ergosterol (3), 3β-hydroxyergosta-7,22-diene (4), 
cerevisterol (5), 3β-O-glucopyranosyl-5,8-epidioxyergosta-6,22-diene (8), 
23-hydroxylanosterol (14) and lanosta-8,23-dien-3β,25-diol (15). 
 
Lactone and terphenyl quinone derivatives from Tapinella 
atrotomentosa 
In the chloroform extract of T. atrotomentosa four compounds (16-19) were 
identified, which had previously been isolated from this species. Two 
compounds were confirmed as lactone type metabolites, osmundalactone 
(16) and 5-hydroxy-2-hexen-4-olide (17), while the other isolated 
metabolites, namely spiromentin C (18) and spiromentin B (19) possess 
terphenyl quinone skeleton. Spiromentins B-C have unique γ- and 
δ-lactone-acetal spiro structures linked to a 4,5-dihydroxy-1,2-
benzoquinone core. 
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Pharmacological activities of isolated compounds 
Antiproliferative effect of the cyclopeptides of G. fusipes 
Gymnopeptides A (1) and B (2) were evaluated for their antiproliferative 
properties against five different human cancer cell lines (HeLa, A431, 
MCF-7, MDA-MB-231 and T47D). Compounds 1 and 2 demonstrated very 
strong cell growth inhibitory activity with IC50 values in nanomolar range 
(14-88 nM). 
Biological activity of the compounds of T. populinum 
Compounds 5-8 identified in the n-hexane extract of T. populinum, were 
assayed for their cytotoxic activity on several human breast cancer cell 
lines (MCF-7, T47D and MDA-MB-231). Cerevisterol (5) and 
3β-O-glucopyranosyl-5,8-epidioxyergosta-6,22-diene (8) proved to be the 
most active against T47D cells (50.2 ± 1.6% and 46.0 ± 1.4% cell growth 
inhibition), while methylated derivative of cerevisterol (7) demonstrated 
significant activity on MDA-MB-231 cells (54.7 ± 1.6%). Compounds 9-12 
were evaluated for their potential XO inhibitory activity; however they 
do not possess inhibitory activity on this enzyme. 
Antiproliferative activity of the secondary metabolites of S. bovista 
Compounds 8, 13-15 were tested for their in vitro antiproliferative activity 
on four different cancer cell lines (HeLa, A2780, MDA-MB-231 and 
MCF-7). Lanosta-8,23-dien-3β,25-diol (15) exhibited higher 
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antiproliferative property on HeLa (62.21 ± 1.95%) and MCF-7 
(73.32 ± 2.76%) cells than 23-hydroxylanosterol (14) (42.88 ± 7.79% and 
37.39 ± 5.89%), but the latter was more effective against A2780 cells. 
3β-O-glucopyranosyl-5,8-epidioxyergosta-6,22-diene (8) showed 
significant activity on A2780 cells (53.27 ± 6.37%), while 
cerebroside B (13) exerted moderate antiproliferative activity. 
Bioactivity of the compounds of T. atrotomentosa 
Antimicrobial activity 
Compounds 16-19 obtained from the chlorofom extract of T. atrotomentosa 
were evaluated for their antimicrobial activity against several bacterial 
strains (Table 1). Our investigations revealed that A. baumanii and ESBL 
E. coli are the most susceptible against the studied compounds. 5-hydroxy-
2-hexen-4-olide (17) was the most active against these strains, although 
osmundalactone (16) and spiromentin C (18) have also shown significant 
effectiveness. Compounds 16-19 were investigated their synergistic effect 
with cefuroxime against MRSA, though our results indicate that they do not 
enhance the activity of the studied antibiotic drug. 
Table 1. Antimicrobial activity of compounds 16-19  
Compounds 
Calculated MIC values (µg mL-1) 
Acinetobacter 
baumannii 
ESBL 
Escherichia. 
coli 
Moraxella 
catarrhalis 
MRSA 
16 10 10 - 250 
17 6 10 50 250 
18 20 10 50 250 
19 - 100 - - 
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Antioxidant activity 
 Compounds 16-19 were evaluated for their antioxidant activity using 
DPPH and ORAC assays. In contrast to the DPPH test, the metabolites 
have shown strong antioxidant activity on ORAC assay. 
Spiromentins C (18) and B (19) demonstrated remarkable antioxidant 
properties, which were higher than the activity of ascorbic acid used as 
reference compound (Table 2). Although osmundalactone (16) and 
5-hydroxy-2-hexen-4-olide (17) were less active in the ORAC assay, they 
are still considered compounds with moderate antioxidant property. The 
DPPH assay performed revealed that compounds 16 and 17 have no 
antioxidant activity in this assay, while compounds 18 and 19 could not be 
evaluated in this assay due to their color interference with the applied 
reagent. 
  
Table 2. Antioxidant activity of compounds 16-19 
Compounds 
ORAC antioxidant activity 
(mmolTE/g) 
16 0.74 ± 0.30 
17 3.85 ± 0.34 
18 16.21 ± 0.38 
19 11.23 ± 0.58 
Ascorbic acid 6.97 ± 0.01 
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